110 related articles for article (PubMed ID: 6195483)
21. Comparison of prizidilol, a new antihypertensive drug with combined arteriolar vasodilator and beta-adrenoceptor blocking actions, with hydralazine and propranolol in conscious dogs with chronic atrioventricular block.
Boucher M; Dubray C; Duchêne-Marullaz P
J Cardiovasc Pharmacol; 1983; 5(5):712-6. PubMed ID: 6195455
[TBL] [Abstract][Full Text] [Related]
22. Prizidilol in essential hypertension: long-term effects on plasma volume, extracellular fluid volume, and central hemodynamics at rest and during exercise.
Lund-Johansen P; Omvik P
J Cardiovasc Pharmacol; 1982; 4(6):1012-7. PubMed ID: 6185765
[TBL] [Abstract][Full Text] [Related]
23. Antihypertensive activity of a new vasodilator, cadralazine, administered alone or in combination with a beta-blocker.
Buoninconti R; Motolese M
Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):613-6. PubMed ID: 2867048
[TBL] [Abstract][Full Text] [Related]
24. Antihypertensive efficacy of a new long acting hydralazine like vasodilator, ISF 2469 in combination with a betablocker and a diuretic.
van Brummelen P; Bühler FR; Kiowski W; Bolli P; Bertel O
Int J Clin Pharmacol Biopharm; 1979 Oct; 17(10):380-5. PubMed ID: 40887
[No Abstract] [Full Text] [Related]
25. Pharmacological properties of the stereoisomers of prizidilol: their use in analysis of reflex tachycardia and blood pressure control in normotensive cats, rats, and dogs.
Owen DA; Eden RJ; Lamb MS; Taylor EM
J Cardiovasc Pharmacol; 1986; 8(4):743-8. PubMed ID: 2427813
[TBL] [Abstract][Full Text] [Related]
26. Dose-response curve and time course of the antihypertensive effect of SKF 92 657, a beta-receptor-blocking and vasodilating compound.
Leonetti G; Terzoli L; Sala C; Bianchini C; Zanchetti A
Clin Sci (Lond); 1980 Dec; 59 Suppl 6():461s-463s. PubMed ID: 6108817
[TBL] [Abstract][Full Text] [Related]
27. Comparison of once daily endralazine with placebo in the treatment of hypertension uncontrolled by a beta-blocker and diuretic.
McGourty JC; Silas JH; Pidgeon J
Eur J Clin Pharmacol; 1985; 29(4):401-3. PubMed ID: 2868900
[TBL] [Abstract][Full Text] [Related]
28. Cadralazine, a new vasodilator, in addition to a beta-blocker for long-term treatment of hypertension.
Salvadeo A; Villa G; Segagni S; Piazza V; Picardi L; Romano M; Parini J
Arzneimittelforschung; 1985; 35(3):623-5. PubMed ID: 2859865
[TBL] [Abstract][Full Text] [Related]
29. Clinical evaluation of endralazine (BO22708), a new vasodilator, in essential hypertension.
Elliott HL; McLean K; Sumner DJ; Donnelly RJ; Reid JL
Clin Exp Hypertens A; 1982; 4(8):1409-18. PubMed ID: 6749347
[TBL] [Abstract][Full Text] [Related]
30. Therapy with hydrazinopyridazine, a new antihypertensive vasodilatory agent, in combination with beta-receptor blocking substances.
Kirch W; von Gizycki C
Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):233-5. PubMed ID: 6104636
[No Abstract] [Full Text] [Related]
31. Cadralazine versus prazosin as second-step treatment in hypertensive patients on beta-blockers: a randomized multicentre study. The Italian Multicentre Study Group.
Caponnetto S; Valvo E; Mocarelli P; Alberti D; Savonitto S
Eur J Clin Pharmacol; 1991; 40(5):461-5. PubMed ID: 1679390
[TBL] [Abstract][Full Text] [Related]
32. A comparison of carvedilol with atenolol in the treatment of mild-to-moderate essential hypertension. INT-CAR-07 (U.K.) Study Group.
Young PH
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S82-5. PubMed ID: 1378155
[TBL] [Abstract][Full Text] [Related]
33. [Continuous intra-arterial pressure recording for 24 hours under basal conditions and during therapy with prizidilol, a vasodilating and beta-blocking drug].
Fariello R; Alicandri C; Boni E; Montini E; Minniti P; Cinquegrana A; Guarienti P; Zaninelli A; Agabiti-Rosei E; Muiesan G
Cardiologia; 1983 Feb; 28(2):127-31. PubMed ID: 6142722
[No Abstract] [Full Text] [Related]
34. Clinical efficacy of carvedilol in severe hypertension.
Ogihara T; Yoshinaga K; Kamahara Y; Ikeda M; Goto Y; Arakawa K; Iimura I; Ishii M; Kokubu T; Takeda T
J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S69-72. PubMed ID: 1721983
[TBL] [Abstract][Full Text] [Related]
35. Ketanserin in combination with beta-adrenergic receptor blocking agents in the treatment of essential hypertension.
Hedner T; Persson B
Br J Clin Pharmacol; 1984 Nov; 18(5):765-71. PubMed ID: 6150724
[TBL] [Abstract][Full Text] [Related]
36. An analysis of blood pressure effects of nipradilol and prizidilol in normotensive and spontaneously hypertensive rats.
Watanabe TX; Sokabe H; Kawashima K
Jpn J Pharmacol; 1985 Jul; 38(3):273-9. PubMed ID: 3903298
[TBL] [Abstract][Full Text] [Related]
37. Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.
Br J Clin Pharmacol; 1988 Nov; 26(5):535-45. PubMed ID: 2905154
[TBL] [Abstract][Full Text] [Related]
38. Effect of long-term carvedilol therapy on renal function in essential hypertension.
Tomita K; Marumo F
J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S97-101. PubMed ID: 1378158
[TBL] [Abstract][Full Text] [Related]
39. [Behavior of arterial pressure, hemodynamic parameters, sympathetic nervous system activity and plasma volume during treatment with a vasodilating and beta-blocking drug in essential hypertension patients].
Fariello R; Alicandri C; Agabiti-Rosei E; Romanelli G; Montini E; Muiesan ML; Minniti P; Castellano M; Beschi M; Boni E; Zaninelli A; Micheli P; Platto L; Leto Di Priolo S; Muiesan G
Boll Soc Ital Cardiol; 1981; 26(11):1871-4. PubMed ID: 6129877
[No Abstract] [Full Text] [Related]
40. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients.
Eggertsen R; Andrén L; Sivertsson R; Hansson L
Eur J Clin Pharmacol; 1984; 27(1):19-22. PubMed ID: 6149128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
